[대기업집단 공시 대해부] 반도체 이후 준비하는 삼성

Samsung's earnings are heavily concentrated in semiconductors, which are booming due to AI server demand, but the conglomerate is strategically diversifying into biotech and senior care to reduce this dangerous dependency. The expansion of Samsung BioLogics' CDMO business and the establishment of Samsung NobleLife reflect management's plan to build sustainable revenue drivers beyond semiconductors. With construction, IT services, and other non-semiconductor divisions facing growth challenges, these emerging businesses have become critical to Samsung's long-term portfolio sustainability.